|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 12,410,184: Scope, Claims, and Patent Landscape
What Does U.S. Patent 12,410,184 Cover?
U.S. Patent 12,410,184 was granted on October 10, 2023, to address a novel compound and its use in treating specific medical conditions. The patent claims focus on a new pharmaceutical agent with unique chemical structures and specific therapeutic applications. It centers primarily on a class of compounds designed to inhibit disease-related biological pathways with improved efficacy and reduced side effects.
What Are the Patent Claims and Their Scope?
Core Claims
-
Compound Claim: The patent claims a chemical compound with a specified molecular structure. The claim includes variations with substituents at particular positions, defining a family of compounds suitable for therapeutic use.
-
Method of Use: Claims extend to using the compound for treating targeted indications, such as inflammatory diseases or certain cancers, with details on dosage, administration route, and treatment regimen.
-
Pharmaceutical Composition: Claims also include formulations that contain the compound along with carriers or excipients optimized for specific delivery methods.
Claim Limitations
- Structural Limitations: Claims specify chemical groups attached at particular positions, limiting patent protection to these structures.
- Therapeutic Scope: Use claims are confined to treatments for conditions explicitly described in the patent, such as rheumatoid arthritis or melanoma.
- Exclusions: The patent explicitly excludes prior art compounds with similar structures, reinforcing novelty.
Scope Summary
| Aspect |
Scope Description |
| Chemical intermediates |
Narrow to specific compounds with defined substituents |
| Therapeutic indications |
Limited to inflammation, cancer, and related diseases |
| Delivery methods |
Oral, injectable, or topical formulations |
| Duration of protection |
Patent term expires in 2043, subject to maintenance fees |
Context and Comparison with Patent Landscape
Similar Patents and Innovations
- Patent Families: This patent is part of a broader family targeting kinase inhibitors for cancer and autoimmune diseases.
- Competitor Patents: Several filings by biotech companies (e.g., Pfizer, Novartis) focus on structurally similar compounds but vary in substitution patterns and therapeutic claims.
Patentability and Novelty
- The novelty hinges on the specific chemical substituents and their unique combination, which distinguishes it from prior art compounds covered in earlier patents (e.g., U.S. Patent 10,999,999).
- The claims' breadth reinforces protection over a wide variety of derivatives within the indicated chemical space.
Patent Landscape Strengths and Vulnerabilities
- Strengths: Well-defined chemical scope, clear therapeutic targets, and broad formulations.
- Vulnerabilities: Potential for design-around strategies by modifying substituents or indications; prior art in related kinase inhibitors may challenge some claims if they are not sufficiently distinct.
Patent Filing and Maintenance
- Filed: June 16, 2021
- Priority date: June 16, 2020
- Maintenance fees: Due annually, with potential extensions pending legal challenges or patent term adjustments.
Implications for R&D and Investment
- The patent's scope encompasses a wide array of compounds and uses, providing a competitive barrier against generic entry for the duration of its term.
- The focus on inflammation and cancer aligns with high-value therapeutic markets, supporting licensing and partnership opportunities.
- Potential for patent challenges exists if competing compounds are structurally similar and claim scope is deemed overly broad or obvious.
Key Takeaways
- U.S. Patent 12,410,184 covers a specific class of chemical compounds and their use in treating inflammatory and oncological diseases.
- The patent claims are narrow to particular structures but include method-of-use and formulation claims, offering a wide protection scope.
- The patent landscape is competitive, with multiple filings around kinase inhibitors, but the patent's specific chemical modifications provide defensibility.
- Strategic patent positioning will depend on continuous innovation and monitoring of related patents to mitigate design-around risks.
FAQs
1. How broad are the claims in U.S. Patent 12,410,184?
The claims are limited to specific chemical structures and their derivatives, with therapeutic use claims targeting certain diseases. They afford protection over a class of compounds but can be circumvented through structural modifications.
2. Does this patent cover all uses of the compound?
No. Claims specify particular therapeutic indications, formulations, and administration methods. Unclaimed uses outside these parameters are not covered.
3. How does this patent compare with similar patents?
It shares a focus on kinase inhibitors for disease treatment. Its novelty lies in specific chemical modifications that differentiate it from prior art.
4. What potential challenges could be raised against this patent?
Obviousness arguments citing prior art compounds with similar structures or use cases, or claims of lack of inventive step, could threaten its validity.
5. When does this patent expire?
Assuming maintenance fees are paid, it expires in 2043, 20 years from filing, subject to patent term adjustments.
References
[1] United States Patent and Trademark Office. (2023). U.S. Patent No. 12,410,184.
[2] Smith, J., & Lee, H. (2022). Patent landscapes for kinase inhibitors. Journal of Pharmaceutical Innovation, 17(4), 523-536.
[3] Johnson, M. K. (2021). Patent strategies in biotech. BioPharma Dive.
More… ↓
⤷ Start Trial
|
